 | | PRD_002253 | | Name: | (2S)-N-{(2S)-3-methoxy-1-[(naphthalen-1-ylmethyl)amino]-1-oxopropan-2-yl}-4-oxo-2-[(3-phenylpropanoyl)amino]-4-(1H-pyrrol-1-yl)butanamide (non-preferred name) | | Formula: | C32 H34 N4 O5 | | Definition date: | 2017-01-11 | | Last modified: | 2023-11-03 |
|
 | | PRD_002254 | | Name: | (2~{S})-~{N}-[(2~{S})-3-methoxy-1-(naphthalen-1-ylmethylamino)-1-oxidanylidene-propan-2-yl]-4-oxidanylidene-2-(3-phenylpropanoylamino)-4-piperidin-1-yl-butanamide | | Formula: | C33 H40 N4 O5 | | Definition date: | 2017-01-11 | | Last modified: | 2023-11-03 |
|
 | | PRD_002255 | | Name: | N,N-diethyl-N~2~-(3-phenylpropanoyl)-L-asparaginyl-N-[(naphthalen-1-yl)methyl]-L-alaninamide | | Formula: | C31 H38 N4 O4 | | Definition date: | 2020-08-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002256 | | Name: | N-tert-butoxy-N~2~-(5-methyl-1,2-oxazole-3-carbonyl)-L-asparaginyl-O-methyl-N-[(naphthalen-1-yl)methyl]-L-serinamide | | Formula: | C28 H35 N5 O7 | | Definition date: | 2017-01-11 | | Last modified: | 2023-11-03 |
|
 | | PRD_002257 | | Name: | Globomycin | | Formula: | C32 H57 N5 O9 | | Definition date: | 2019-08-28 | | Last modified: | 2023-11-03 |
|
 | | PRD_002282 | | Name: | (3S,6S,9S,15aR)-6,9-dibenzyl-3-{6,6-dihydroxy-6-[(2S)-oxiran-2-yl]hexyl}octahydro-2H-pyrido[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10(3H,12H)-tetrone | | Formula: | C34 H44 N4 O7 | | Definition date: | 2017-09-13 | | Last modified: | 2023-11-03 |
|
 | | PRD_002285 | | Name: | N~2~-[(2S)-2-{[3-(6-chloro-1,3-benzothiazol-2-yl)-N-propanoyl-L-alanyl]amino}-2-cyclopentylacetyl]-N-[(4R)-3,4-dihydro-2H-1-benzopyran-4-yl]-N~6~,N~6~-dimethyl-L-lysinamide | | Formula: | C37 H49 Cl N6 O5 S | | Definition date: | 2018-02-28 | | Last modified: | 2023-11-03 |
|
 | | PRD_002289 | | Name: | 3-[(3R,6S,9S,12S,15S,18S,21S,24R,27S)-21-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,24,27-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29-decaoxo-12-(propan-2-yl)-2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29-octacosahydro-1H-1,4,7,10,13,16,19,22,25,28-benzodecaazacyclohentriacontin-18-yl]propanamide | | Formula: | C68 H85 N13 O13 | | Definition date: | 2020-08-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000672 | | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-CO-NH-CH2PH | | Formula: | C35 H44 N6 O14 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002290 | | Name: | 4-[(3R,6S,9S,12S,15S,18S,21S,24R,27S)-21-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,24,27-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29-decaoxo-12-(propan-2-yl)-2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29-octacosahydro-1H-1,4,7,10,13,16,19,22,25,28-benzodecaazacyclohentriacontin-18-yl]butan-1-aminium | | Formula: | C69 H90 N13 O12 | | Definition date: | 2020-08-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000673 | | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-COO-CH2PH | | Formula: | C35 H43 N5 O15 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000674 | | Name: | CBZ-ASP-GLU-VAL-azaASP-EP-CO-N(CH2PH)2 | | Formula: | C42 H50 N6 O14 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002314 | | Name: | INNN(ABU) Cyclic peptide inhibitor | | Formula: | C22 H36 N8 O8 | | Definition date: | 2019-04-17 | | Last modified: | 2023-11-03 |
|
 | | PRD_000727 | | Name: | PYOVERDIN G173 Fe Complex | | Formula: | C49 H66 Fe N13 O21 | | Description: | IN IRON-DEFICIENT CONDITIONS, PSEUDOMONAS
AERUGINOSA SECRETES A MAJOR FLUORESCENT
SIDEROPHORE NAMED PYOVERDIN (PVD),
WHICH AFTER CHELATING IRON(III) IS TRANSPORTED
BACK INTO THE CELL VIA ITS OUTER MEMBRANE RECEPTOR
FPVA. FPVA IS A TONB-DEPENDENT TRANSPORT PROTEIN
AND HAS THE ABILITY TO BIND PVD IN ITS APO-
OR IRON-LOADED FORM. | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000770 | | Name: | (5S, 8R, 11S)-14-[4-(BENZYLOXY)-4-OXOBUTANOYL]-8-(2-CARBOXYETHYL)-5-(CARBOXYMETHYL)-11-
(1-METHYLETHYL)-3,6,9,12-TETRAOXO-1-PHENYL-2-OXA-4,7,10,13,14-PENTAAZAHEXADECAN-16-OIC ACID | | Formula: | C35 H43 N5 O14 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002350 | | Name: | INHIBITOR ARC-1415 | | Formula: | C55 H106 N30 O8 | | Definition date: | 2021-08-04 | | Last modified: | 2023-11-03 |
|
 | | PRD_000781 | | Name: | Thr-Asp-F-amidine | | Formula: | C17 H29 F N6 O7 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002363 | | Formula: | C73 H120 N20 O13 | | Definition date: | 2020-08-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_000785 | | Name: | Largazole | | Formula: | C21 H29 N4 O4 S3 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002365 | | Name: | phazolicin | | Formula: | C74 H104 N29 O27 S3 | | Definition date: | 2020-08-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_002369 | | Name: | ecumicin | | Formula: | C83 H135 N14 O17 | | Definition date: | 2020-05-13 | | Last modified: | 2023-11-03 |
|
 | | PRD_002390 | | Name: | Papain-like protease peptide inhibitor VIR251 | | Formula: | C22 H33 N5 O7 | | Definition date: | 2020-05-20 | | Last modified: | 2023-11-03 |
|
 | | PRD_002391 | | Name: | covalently bound calpain inhibitor II | | Formula: | C19 H37 N3 O4 S | | Definition date: | 2020-06-17 | | Last modified: | 2023-11-03 |
|
 | | PRD_002392 | | Name: | UAW246 | | Formula: | C25 H36 N4 O6 | | Definition date: | 2020-06-17 | | Last modified: | 2023-11-03 |
|
 | | PRD_000814 | | Name: | N-{[(3R,4R,7S,10R,11R)-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-7-(propan-2-yl)-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(16),12,14-trien-4-yl]carbonyl}glycine | | Formula: | C23 H34 N4 O8 | | Definition date: | 2012-12-12 | | Last modified: | 2023-11-03 |
|
